Calciphylaxis Treatment Market Report 2026

Calciphylaxis Treatment Market Overview

• Calciphylaxis Treatment market size has reached to $2.03 billion in 2025 • Expected to grow to $3.03 billion in 2030 at a compound annual growth rate (CAGR) of 8.3% • Growth Driver: Elevated Kidney Disease Prevalence Fuels Calciphylaxis Treatment Market Growth • Market Trend: Advanced Diagnostic Solutions Drive Profitability And Improve Care In The Calciphylaxis Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Calciphylaxis Treatment Market?

Calciphylaxis, or calcific uremic arteriolopathy (CUA), is a rare and severe medical condition characterized by the calcification or deposition of calcium in small blood vessels and tissues, primarily in individuals with kidney disease, especially end-stage renal disease (ESRD). It’s treatment function involves pain management and nutritional support therapies to manage and alleviate symptoms such as painful and non-healing skin ulcers, tissue necrosis, and complications such as sepsis, which can be life-threatening. The main types of calciphylaxis treatment are medication, hyperbaric oxygen therapy, and others. Medication refers to the use of pharmaceutical drugs to manage and alleviate the symptoms and underlying causes of a medical condition, and medications such as sodium thiosulfate, opioids, or non-opioid drugs are used to treat or prevent infections, manage pain, and are associated with calciphylaxis. It is diagnosed with imaging, blood tests, and deep skin biopsies by end users such as hospitals, clinics, medical research centers, and academic institutes.

What Is The Calciphylaxis Treatment Market Growth Forecast?

The calciphylaxis treatment market size is expected to see strong growth in the next few years. It will grow to $3.03 billion in 2030 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to increasing development of targeted drug therapies, rising adoption of combination treatment approaches, expansion of specialized calciphylaxis treatment centers, growing investment in rare disease therapeutics, increasing focus on improving patient survival outcomes. Major trends in the forecast period include increasing use of sodium thiosulfate therapy, rising adoption of hyperbaric oxygen treatment, growing focus on multidisciplinary disease management, expansion of advanced wound care interventions, enhanced emphasis on early therapeutic intervention.

Global Calciphylaxis Treatment Market Segmentation

1) By Type: Medication, Hyperbaric Oxygen Therapy, Other Types 2) By Diagnosis: Imaging, Blood Tests 3) By End User: Hospitals, Clinics, Medical Research Centers Subsegments: 1) By Medication: Sodium Thiosulfate, Bisphosphonates, Cinacalcet 2) By Hyperbaric Oxygen Therapy: Monoplace Hyperbaric Oxygen Therapy, Multiplace Hyperbaric Oxygen Therapy 3) By Other Types: Dialysis, Wound Care And Management

What Is The Driver Of The Calciphylaxis Treatment Market?

The growing prevalence of kidney diseases is expected to propel the growth of the calciphylaxis treatment market going forward. Kidney diseases refer to a wide range of medical conditions and disorders that affect the kidneys, vital organs that filter waste products, and excess fluids from the bloodstream to form urine. Kidney diseases disrupt calcium and phosphate metabolism, increasing the risk of calciphylaxis and necessitating the development of diagnostic and treatment strategies to address the condition. For instance, in June 2023, according to Kidney Research UK, a UK-based charitable organization, an estimated 7.19 million people in the UK were affected by chronic kidney disease in 2023, representing more than 10% of the UK population and projected to increase to 7.61 million people by 2033. Therefore, the growing prevalence of kidney diseases will drive the growth of the calciphylaxis treatment industry.

Key Players In The Global Calciphylaxis Treatment Market

Major companies operating in the calciphylaxis treatment market are Pfizer Inc., Merck And Co. Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca Plc, Sanofi SA, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Novo Nordisk, Viatris, Regeneron Pharmaceuticals Inc., Incyte Corporation, Vifor Pharma Group, Panion And BF Biotech Inc., Inozyme Pharma Inc., Sanifit Therapeutics S.A., Hope Pharmaceuticals, Menlo Therapeutics

Global Calciphylaxis Treatment Market Trends and Insights

Major companies operating in the calciphylaxis treatment market are developing advanced diagnostic techniques and health evaluation kits and services such as in-home chronic kidney disease diagnostic and preventive services deployment to enhance early detection and patient-centric care outcomes. In-home chronic kidney disease diagnostic and preventive services deployment refers to a structured program designed to provide kidney health assessment, early detection of chronic kidney disease, and preventive healthcare interventions directly at patients’ homes, aiming to improve patient outcomes, increase accessibility to diagnostics, and reduce the burden on traditional healthcare facilities. For instance, in August 2023, Signify Health, Inc., a US-based healthcare company, introduced a comprehensive in-home kidney health evaluation as an addition to its diagnostic and preventive services aimed at aiding in the early detection, diagnosis, and management of chronic kidney health issues. Urinalysis (uACR) and an estimated glomerular filtration rate (eGFR) are included in the in-home health assessments and kidney assessment, giving crucial information for treatment options such as additional tests, lifestyle changes, medication, or referral to a nephrologist. This service is especially advantageous for illnesses such as calciphylaxis, a rare disorder characterized by calcium deposits in tiny arteries associated with end-stage renal failure, allowing for early identification and treatment.

What Are Latest Mergers And Acquisitions In The Calciphylaxis Treatment Market?

In January 2024, Merck KGaA, a Germany-based science and technology company that provides calciphylaxis treatment partnered with Inspirna Inc. With this partnership, Merck KGaA expanded its colorectal cancer portfolio through a licensing agreement for the drug ompenaclid (RGX-202). This first-in-class oral inhibitor targets the creatine transport channel SLC6A8 and is currently in Phase II development for advanced RAS-mutated colorectal cancer (mCRC). Inspirna Inc. is a US-based clinical-stage biopharmaceutical company.

Regional Outlook

North America was the largest region in the calciphylaxis treatment market in 2025 Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Calciphylaxis Treatment Market?

The calciphylaxis treatment market consists of revenues earned by entities by providing diagnostic services such as infrared thermography, electrolyte and mineral analysis, and measuring serum parathyroid hormone (PTH) levels to diagnose and assess the severity of calciphylaxis in patients. The market value includes the value of related goods sold by the service provider or included within the service offering. The calciphylaxis treatment market also includes sales of intensive wound care, clot-dissolving therapy, and vitamin K therapy, which are comprehensive treatment approaches for managing calciphylaxis. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Calciphylaxis Treatment Market Report 2026?

The calciphylaxis treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the calciphylaxis treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.